Medirom Healthcare Prices $10M Share Offering
Ticker: MRM · Form: 6-K · Filed: Dec 12, 2024 · CIK: 1819704
Sentiment: neutral
Topics: public-offering, equity-raise, underwriting-agreement
TL;DR
Medirom prices $10M share offering, closing Dec 12.
AI Summary
On December 9, 2024, Medirom Healthcare Technologies Inc. entered into an underwriting agreement with ThinkEquity LLC for a public offering of 2,860,000 common shares. The offering is expected to close on December 12, 2024, with gross proceeds of approximately $10.0 million before deducting underwriting discounts and commissions.
Why It Matters
This capital raise provides Medirom with funds that can be used for general corporate purposes, potentially fueling expansion or operational improvements.
Risk Assessment
Risk Level: medium — Public offerings can dilute existing shareholders and the success of the offering depends on market conditions.
Key Numbers
- $10.0M — Gross Proceeds (Expected funds raised from the public offering before expenses.)
- 2,860,000 — Shares Offered (The total number of common shares being sold in the public offering.)
Key Players & Entities
- Medirom Healthcare Technologies Inc. (company) — The company conducting the share offering.
- ThinkEquity LLC (company) — The underwriter for the public offering.
- December 9, 2024 (date) — Date the underwriting agreement was entered into.
- 2,860,000 (dollar_amount) — Number of common shares to be offered.
- $10.0 million (dollar_amount) — Gross proceeds expected from the offering.
- December 12, 2024 (date) — Expected closing date of the offering.
FAQ
What is the purpose of the public offering?
The filing states the proceeds are intended for general corporate purposes.
Who is the underwriter for this offering?
ThinkEquity LLC is the underwriter for the offering.
What is the expected closing date of the offering?
The offering is expected to close on December 12, 2024.
How many shares are being offered?
The company is offering 2,860,000 common shares.
What are the estimated gross proceeds from the offering?
The estimated gross proceeds are approximately $10.0 million.
Filing Stats: 1,184 words · 5 min read · ~4 pages · Grade level 14.6 · Accepted 2024-12-12 06:41:55
Key Financial Figures
- $1.75 — ry Shares (the "ADSs") at sale price of $1.75 per ADS, generating gross proceeds of $
- $5,005,000 — 5 per ADS, generating gross proceeds of $5,005,000. The Company also granted the Underwrit
- $3.8 m — aggregate net proceeds of approximately $3.8 million, after deducting underwriting dis
- $2.1875 — its designees, at an exercise price of $2.1875 per ADS (the "Underwriter Warrants"). T
Filing Documents
- tmb-20241209x6k.htm (6-K) — 23KB
- tmb-20241209xex1d1.htm (EX-1.1) — 564KB
- tmb-20241209xex99d1.htm (EX-99.1) — 9KB
- tmb-20241209xex99d2.htm (EX-99.2) — 9KB
- tmb-20241209xex1d1002.jpg (GRAPHIC) — 2KB
- 0001558370-24-016167.txt ( ) — 609KB
Forward-Looking Statements Regarding the Company
Forward-Looking Statements Regarding the Company Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about the Company's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design," "target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate," "estimate," "believe," "continue," "predict," "project," "potential," "goal," or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More information on these risks and other potential factors that could affect the Company's business, reputation, results of operations, financial condition, and stock price is inclu
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 12, 2024 MEDIROM HEALTHCARE TECHNOLOGIES INC. By: /s/ Fumitoshi Fujiwara Name: Fumitoshi Fujiwara Title: Chief Financial Officer